- Home
- PRK vs QURE Comparison
PRK vs QURE Comparison
Compare PRK & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRK | QURE |
|---|---|---|
| Founded | 1908 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PRK | QURE |
|---|---|---|
| Price | $191.67 | $47.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $184.00 | $45.00 |
| AVG Volume (30 Days) | 67.5K | ★ 1.0M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | 19.21 | ★ 29.67 |
| EPS | ★ 5.64 | N/A |
| Revenue | ★ $664,421,000.00 | $13,107,000.00 |
| Revenue This Year | $24.26 | $126.12 |
| Revenue Next Year | $3.63 | $200.43 |
| P/E Ratio | $34.63 | ★ N/A |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $149.06 | $8.73 |
| 52 Week High | $215.00 | $71.50 |
Technical Indicators
Market Signals| Indicator | PRK | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 55.78 |
| Support Level | $181.01 | $46.34 |
| Resistance Level | $192.77 | $51.09 |
| Average True Range (ATR) | 4.14 | 1.92 |
| MACD | -1.97 | -0.24 |
| Stochastic Oscillator | 8.62 | 49.73 |
Price Performance
Historical ComparisonAbout PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.